GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » Equity-to-Asset

Abattis Bioceuticals (Abattis Bioceuticals) Equity-to-Asset : 0.58 (As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Abattis Bioceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $8.37 Mil. Abattis Bioceuticals's Total Assets for the quarter that ended in Sep. 2019 was $14.55 Mil. Therefore, Abattis Bioceuticals's Equity to Asset Ratio for the quarter that ended in Sep. 2019 was 0.58.

The historical rank and industry rank for Abattis Bioceuticals's Equity-to-Asset or its related term are showing as below:

ATTBF's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.58
* Ranked among companies with meaningful Equity-to-Asset only.

Abattis Bioceuticals Equity-to-Asset Historical Data

The historical data trend for Abattis Bioceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals Equity-to-Asset Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.53 1.26 1.01 0.58

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 1.00 1.01 0.59 0.58

Competitive Comparison of Abattis Bioceuticals's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's Equity-to-Asset falls into.



Abattis Bioceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Abattis Bioceuticals's Equity to Asset Ratio for the fiscal year that ended in Sep. 2019 is calculated as

Equity to Asset (A: Sep. 2019 )=Total Stockholders Equity/Total Assets
=8.366/14.546
=0.58

Abattis Bioceuticals's Equity to Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

Equity to Asset (Q: Sep. 2019 )=Total Stockholders Equity/Total Assets
=8.366/14.546
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abattis Bioceuticals  (OTCPK:ATTBF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Abattis Bioceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (Abattis Bioceuticals) Headlines